Characterization of immune profile in an aging multiple sclerosis clinic population

• DOI: 10.1016/j.msard.2022.103818
• Publication Date: 2022-04-25T09:04:54Z
• Authors: Andrew P. Keegan; Utsav Joshi; Laila Abdullah; Daniel Paris; Teresa Darcey; Daniel Niedospial; Lois A. Davis; Fiona Crawford; Michael Mullan
• Keywords: 0301 basic medicine; Aging; 03 medical and health sciences; Multiple Sclerosis; Cytokines; Humans; Glatiramer Acetate; Middle Aged; Interleukin-10; 3. Good health

There is limited data regarding adaptive immunity in older persons with Multiple Sclerosis (MS).The aim of the present study was to quantify adaptive immune cells in younger (age less than 50) and older (age greater than 50) with MS in the context of clinical parameters (EDSS, 25-foot walk, SDMT). Subjects were either Untreated (no MS medications in 6 months), taking Injectables (interferons or glatiramer acetate), or Other approved MS treatments.A total of 72 subjects were enrolled (30 younger and 42 older). Older MS patients that were Untreated or taking Injectables had lower CD8 cell counts. Older MS patients demonstrated increased levels of CD4+CD25hi cells and inflammatory serum cytokines (TNF-α, IL-8). There was suggestion that MS treatments modulated IL-10. Cognition as assessed by SDMT was associated with disease duration and IL-10.Components of adaptive immunity are influenced by aging in MS which may also impact aspects of cognition as measured by SDMT.